A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...
IPF has a high unmet need for patients, and we are continuously fostering our research activities to develop more options for one of the most common interstitial lung diseases.” Nerandomilast is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback